Abstract
Local recurrence (LR) after curative surgery is a critical problem for patients with colorectal cancer (CRC). Over the last two decades, oncologic treatment results for primary rectal cancer have improved due to refinements in neoadjuvant chemotherapy, radiation, and surgery. Nevertheless, there is still a 5–10% rate of LR, threatening the survival and quality of life of affected patients [1]. LR is best defined as any tumor recurring within the true pelvis, including neorectum, mesentery, pelvic viscera, pelvic sidewall structures, and bone. Due to variability of anatomy and clinical presentation, detection, staging, and clinical management are complex. About half of all LRs are limited to the pelvis and can be considered for curative re-excision [2] (Table 6.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Heriot AG, Byrne CM, Lee P et al (2008) Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum 51:284–291
Heald RJ (1995) Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. Br J Surg 82:1297–1299
Guillem JG, Chessin DB, Cohen AM et al (2005) Longterm oncologic outcome following pre-operative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241:829 (discussion 836–828)
Wanebo HJ, Antoniuk P, Koness RJ et al (1999) Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum 42:1438-1448
Heriot AG, Byrne CM, Lee P et al (2008) Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum 51:284-291
Yamada K, Ishizawat T, Niwa K et al (2001) Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer. Br J Surg 88:988-993
Jimenez RE, Shoup M, Cohen AM et al (2003) Contemporary outcomes of total pelvic exenteration in the treatment of colorectal cancer. Dis Colon Rectum 46:1619-1625
Yeo HL, Paty PB (2014) Management of Recurrent Rectal Cancer: Practical Insights in Planning and Surgical Intervention. J Surg Onc 109:47-52
Bouchard P, Efron J (2010) Management of recurrent rectal cancer. Ann Surg Oncol 17:1343–1356
Primrose JN, Perera R et al (2014) Effect of 3 to 5 years of scheduled CEA and follow-up to detect recurrence of colorectal cancer. The FACS randomized clinical trial. JAMA 311:263-270
Platell C, Spilsbury K (2014) Influence of local recurrence on survival in patients with rectal cancer. ANZ J Surg 84:85–90
Sagar PM, Pemberton JH (1996) Surgical management of locally recurrent rectal cancer. Br J Surg 83:293–304
Lopez-Kostner F, Fazio VW et al (2001) Locally recurrent rectal cancer: predictors and success of salvage surgery. Dis Colon Rectum 44:173–178
Mirnezami AH, Sagar PM et al (2010) Clinical algorithms for the surgical management of locally recurrent rectal cancer. Dis Colon Rectum 53:1248–1257
Harris DA, Davies M et al (2011) Multivisceral resection for primary locally advanced rectal carcinoma. Br J Surg 98:582–588
Nordlinger B et al (2008) Perooperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 371:1007–1016
Haddock MG, Miller RC et al (2011) Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 79:143–150
Heinemann V, von Weikersthal L, Decker T et al (2013) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. J Clin Oncol 31(suppl)
Loupakis F, Cremolini C et al (2014) Initial therapy with FOLFOXIRI and Bevacizumab for metastatic colo rectal cancer. N Engl J Med 371:1609–1618
Falcone A, Cremolini C, Masi G et al (2013) FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group (abstract 3505). J Clin Oncol 31(suppl)
Lee S. Schwartzberg et al (2013) PEAK: a randomized, multicenter phase ii study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS Ex-on 2 metastatic colorectal cancer. J Clin Oncol 32:2240–2247
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1–iii9
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Italia
About this chapter
Cite this chapter
Nappi, A. et al. (2016). Indications for Systemic Chemotherapy. In: Romano, G.M. (eds) Multimodal Treatment of Recurrent Pelvic Colorectal Cancer. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-5767-8_6
Download citation
DOI: https://doi.org/10.1007/978-88-470-5767-8_6
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5766-1
Online ISBN: 978-88-470-5767-8
eBook Packages: MedicineMedicine (R0)